Intranasal treatment with poly(IC) protects aged mice from lethal respiratory virus infections

DOI: 10.1128/jvi.01410-12
Journal of Virology, 2012, 86, 11416-24.

#	Paper	IF	Citations
99	Functional RIG-I-like receptors control the survival of mesenchymal stem cells. *Cell Death and Disease*, **2013**, 4, e967	9.8	25
98	Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo. *Organic and Biomolecular Chemistry*, **2013**, 11, 1049-58	3.9	7
97	Advances in antivirals for non-influenza respiratory virus infections. *Influenza and Other Respiratory Viruses*, **2013**, 7 Suppl 3, 36-43	5.6	32
96	Other viral pneumonias: coronavirus, respiratory syncytial virus, adenovirus, hantavirus. *Critical Care Clinics*, **2013**, 29, 1045-68	4.5	20
95	Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. *Frontiers in Immunology*, **2013**, 4, 387	8.4	185
94	Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. *PLoS Pathogens*, **2013**, 9, e1003298	7.6	76
93	Toll-like receptors in antiviral innate immunity. *Journal of Molecular Biology*, **2014**, 426, 1246-64	6.5	402
92	Novel drugs targeting Toll-like receptors for antiviral therapy. *Future Virology*, **2014**, 9, 811-829	2.4	62
91	Switch from protective to adverse inflammation during influenza: viral determinants and hemostasis are caught as culprits. *Cellular and Molecular Life Sciences*, **2014**, 71, 885-98	10.3	27
90	Innate immune responses and neuroepithelial degeneration and regeneration in the mouse olfactory mucosa induced by intranasal administration of Poly(I:C). *Cell and Tissue Research*, **2014**, 357, 279-99	4.2	42
89	Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. *Journal of Virology*, **2014**, 88, 4180-94	6.6	86
88	Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. *Journal of Virology*, **2014**, 88, 8597-614	6.6	86
87	Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. *Virology*, **2014**, 454-455, 157-68	3.6	57
86	TLR3 mediated innate immune response in mice brain following infection with Chikungunya virus. *Virus Research*, **2014**, 189, 194-205	6.4	41
85	Bacterial lipopolysaccharide inhibits influenza virus infection of human macrophages and the consequent induction of CD8+ T cell immunity. *Journal of Innate Immunity*, **2014**, 6, 129-39	6.9	11
84	[Stimulating Type I interferon response with small molecules: revival of an old idea]. **2015**, 209, 145-59		1
83	Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. *MBio*, **2015**, 6, e00638-15	7.8	293

82	A Toll-Like Receptor 5 Agonist Improves the Efficacy of Antibiotics in Treatment of Primary and Influenza Virus-Associated Pneumococcal Mouse Infections. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6064-72	5.9	30
81	Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. *Journal of Virology*, **2015**, 89, 2995-3007	6.6	136
80	TLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral Infection. *Journal of Immunology*, **2015**, 195, 4387-95	5.3	24
79	Nucleic acid-based drugs against emerging zoonotic viruses. *Future Medicinal Chemistry*, **2015**, 7, 1709-19	4.1	2
78	Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection. *Journal of Experimental Medicine*, **2015**, 212, 1851-68	16.6	81
77	Stimulation of the RIG-I/MAVS Pathway by Polyinosinic:Polycytidylic Acid Upregulates IFN-λ in Airway Epithelial Cells with Minimal Costimulation of IL-8. *Journal of Immunology*, **2015**, 195, 2829-41	5.3	29
76	Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs. *Vaccine*, **2015**, 33, 542-8	4.1	23
75	The amazing innate immune response to influenza A virus infection. *Innate Immunity*, **2015**, 21, 73-98	2.7	59
74	T Cell Responses during Acute Respiratory Virus Infection. **2016**, 324-331		0
73	SARS coronavirus infections of the lower respiratory tract and their prevention. **2016**, 45-53		1
72	Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. *PLoS Pathogens*, **2016**, 12, e1005531	7.6	141
71	Intranasal treatment with a novel immunomodulator mediates innate immune protection against lethal pneumonia virus of mice. *Antiviral Research*, **2016**, 135, 108-119	10.8	6
70	Advances in Antiviral Therapies Targeting Toll-like Receptors. *Expert Opinion on Investigational Drugs*, **2016**, 25, 437-53	5.9	16
69	Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity. *Antiviral Research*, **2016**, 129, 81-92	10.8	1
68	Interferon-mediated antiviral activities of Angelica tenuissima Nakai and its active components. *Journal of Microbiology*, **2016**, 54, 57-70	3	5
67	Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2017**, 9, e1415	9.2	5
66	MERS-coronavirus: From discovery to intervention. *One Health*, **2017**, 3, 11-16	7.6	34
65	Coptidis Rhizoma extract inhibits replication of respiratory syncytial virus in vitro and in vivo by inducing antiviral state. *Journal of Microbiology*, **2017**, 55, 488-498	3	16

64	Induction of a balanced IgG1/IgG2 immune response to an experimental challenge with Mycoplasma bovis antigens following a vaccine composed of Emulsigen IDR peptide1002, and poly I:C. *Vaccine*, **2017**, 35, 6604-6610	4.1	12
63	Pattern recognition receptor immunomodulation of innate immunity as a strategy to limit the impact of influenza virus. *Journal of Leukocyte Biology*, **2017**, 101, 851-861	6.5	13
62	Protective efficacy of combined trivalent inactivated ISA 71 oil adjuvant vaccine against avian influenza virus subtypes (H9N2 and H5N1) and Newcastle disease virus. *Veterinary World*, **2017**, 10, 1212-1220	1.7	4
61	PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials. *Antiviral Research*, **2018**, 153, 70-77	10.8	3
60	BMAL1 links the circadian clock to viral airway pathology and asthma phenotypes. *Mucosal Immunology*, **2018**, 11, 97-111	9.2	65
59	Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia. *JCI Insight*, **2018**, 3,	9.9	20
58	Attenuation of Influenza A Virus Disease Severity by Viral Coinfection in a Mouse Model. *Journal of Virology*, **2018**, 92,	6.6	33
57	Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice. *Mammalian Genome*, **2018**, 29, 367-383	3.2	14
56	Saponin-adjuvanted vaccine protects chickens against velogenic Newcastle disease virus. *Archives of Virology*, **2018**, 163, 2423-2432	2.6	4
55	Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir. *Antiviral Research*, **2019**, 168, 28-35	10.8	12
54	Broad-spectrum coronavirus antiviral drug discovery. *Expert Opinion on Drug Discovery*, **2019**, 14, 397-412	6.2	109
53	A Multi-Omics Study of Chicken Infected by Nephropathogenic Infectious Bronchitis Virus. *Viruses*, **2019**, 11,	6.2	8
52	A dissection of SARS-CoV2 with clinical implications (Review). *International Journal of Molecular Medicine*, **2020**, 46, 489-508	4.4	24
51	Andrographolide sulfate inhibited NF-B activation and alleviated pneumonia induced by poly I:C in mice. *Journal of Pharmacological Sciences*, **2020**, 144, 189-196	3.7	3
50	The immuno-oncological challenge of COVID-19.. *Nature Cancer*, **2020**, 1, 946-964	15.4	52
49	The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. *Frontiers in Immunology*, **2020**, 11, 1712	8.4	128
48	Lessons for COVID-19 Immunity from Other Coronavirus Infections. *Immunity*, **2020**, 53, 248-263	32.3	180
47	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. *Frontiers in Microbiology*, **2020**, 11, 588409	5.7	11

46	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. *Frontiers in Cellular and Infection Microbiology*, **2020**, 10, 575404	5.9	3
45	Immune responses during COVID-19 infection. *OncoImmunology*, **2020**, 9, 1807836	7.2	49
44	Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?. *Frontiers in Immunology*, **2020**, 11, 573662	8.4	29
43	Potential effects of curcumin in the treatment of COVID-19 infection. *Phytotherapy Research*, **2020**, 34, 2911-2920	6.7	132
42	Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight. *Acta Pharmaceutica Sinica B*, **2020**, 10, 1175-1191	15.5	9
41	Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host and Microbe*, **2020**, 27, 870-878	23.4	432
40	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. *International Immunopharmacology*, **2020**, 86, 106717	5.8	53
39	Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective. *International Journal of Biological Macromolecules*, **2020**, 163, 1-8	7.9	42
38	The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies. *International Immunopharmacology*, **2021**, 92, 107051	5.8	14
37	A Missing Link: Engagements of Dendritic Cells in the Pathogenesis of SARS-CoV-2 Infections. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
36	Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	45
35	Association of TLR3 functional variant (rs3775291) with COVID-19 susceptibility and death: a population-scale study. *Human Cell*, **2021**, 34, 1025-1027	4.5	6
34	New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. *Frontiers in Medicine*, **2021**, 8, 640073	4.9	23
33	TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. *JCI Insight*, **2021**, 6,	9.9	2
32	General characteristics of adjuvants and their mechanisms of action (part 2). *BIOpreparations Prevention Diagnosis Treatment*, **2021**, 21, 20-30	0.8	0
31	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. *Trends in Immunology*, **2021**, 42, 312-322	14.4	35
30	Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. *EBioMedicine*, **2021**, 67, 103381	8.8	40
29	Ultraviolet radiation, vitamin D, and COVID-19. *Italian Journal of Dermatology and Venereology*, **2021**, 156, 366-373	1.2	1

28	Emerging Technologies for the Treatment of COVID-19. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 81-96	3.6	2
27	IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. *Journal of Clinical Investigation*, **2019**, 129, 3625-3639	15.9	330
26	Neurological consequences of COVID-19: what have we learned and where do we go from here?. *Journal of Neuroinflammation*, **2020**, 17, 286	10.1	39
25	Evaluation of the Protective Efficacy of Poly I:C as an Adjuvant for H9N2 Subtype Avian Influenza Inactivated Vaccine and Its Mechanism of Action in Ducks. *PLoS ONE*, **2017**, 12, e0170681	3.7	14
24	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. *Vaccines*, **2020**, 8,	5.3	8
23	Systems biology unravels interferon responses to respiratory virus infections. *World Journal of Biological Chemistry*, **2014**, 5, 12-25	3.8	3
22	A formulated poly (I:C)/CCL21 as an effective mucosal adjuvant for gamma-irradiated influenza vaccine. *Virology Journal*, **2021**, 18, 201	6.1	0
21	HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis. *Euroasian Journal of Hepato-gastroenterology*, **2021**, 11, 59-70	1.6	1
20	Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19. *Expert Review of Anticancer Therapy*, **2021**, 21, 1371-1383	3.5	2
19	Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines. *Npj Vaccines*, **2021**, 6, 127	9.5	8
18	Potential treatment of COVID-19 with traditional chinese medicine: What herbs can help win the battle with SARS-CoV-2?. *Engineering*, **2021**,	9.7	2
17	Identification and Development of Therapeutics for COVID-19. *MSystems*, **2021**, e0023321	7.6	5
16	TLRs in COVID-19: How they drive immunopathology and the rationale for modulation. *Innate Immunity*, **2021**, 27, 503-513	2.7	6
15	Immunological status of the olfactory bulb in a murine model of Toll-like receptor 3-mediated upper respiratory tract inflammation.. *Journal of Neuroinflammation*, **2022**, 19, 13	10.1	2
14	Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection.. *Viruses*, **2022**, 14,	6.2	1
13	Innate immunity: the first line of defense against SARS-CoV-2.. *Nature Immunology*, **2022**, 23, 165-176	19.1	37
12	Identification and Development of Therapeutics for COVID-19. **2021**,		
11	Table_1.docx. **2020**,		

10	Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing. *Biomolecules*, **2022**, 12, 690	5.9	0
9	Epigenetic adjuvants: durable reprogramming of the innate immune systemsy with adjuvants.. *Current Opinion in Immunology*, **2022**, 77, 102189	7.8	1
8	More tools for our toolkit: The application of HEL-299 cells and dsRNA-nanoparticles to study human coronaviruses in vitro. **2022**, 321, 198925		0
7	Complementary and Alternative Medicine in COVID-19 Infection, an Old Weapon Against a New Enemy.		0
6	Cytokine storm and neuropathological alterations in patients with neurological manifestations of COVID-19. **2022**, 19,		1
5	Cellular Landscaping of COVID-19 and Gynaecological Cancers: An Infrequent Correlation. **2022**, 2022, 1-15		0
4	Immune response induced by novel coronavirus infection. 12,		1
3	Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. **2022**, 20,		1
2	Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B. **2022**, 10, 2087		0
1	Antiviral Approaches against Influenza Virus.		1